# AmMax Bio., Inc.

> AmMax Bio is a clinical-stage biotechnology company in Redwood City, California, developing first-in-class cancer therapeutics built on a CSF1R-targeting antibody platform. Founded in 2020 by pharmaceutical veteran Larry Hsu, PhD, in partnership with Amgen, the company advances a pipeline that spans a monoclonal antibody for tenosynovial giant cell tumor (TGCT), a therapy for colorectal cancer minimal residual disease (in partnership with MD Anderson), and a lead antibody-drug conjugate, AMB-104, for acute myeloid leukemia. AmMax's strategy is to de-risk development by combining clinically validated antibodies with established linker-payload technology.

- **Founded:** 2020
- **Headquarters:** Redwood City, California, United States
- **Founders:** Larry Hsu (Founder & CEO)
- **Team size:** ~12 employees
- **Products:** AMB-104, AMB-066, AMB-05X, AMB-051
- **Notable:** Built a three-program oncology pipeline from a single clinically-validated CSF1R antibody., Secured FDA Fast Track and EMA PRIME designations for its CSF1R antibody in TGCT., Dosed first patient in a Phase 2a colorectal cancer MRD study (early 2025).

## Products & services

- **AMB-104** — Lead program: a novel antibody-drug conjugate combining AmMax's clinically-validated CSF1R monoclonal antibody with Lonza's exatecan-based SYNtecan linker-payload platform, designed to directly kill monocytic AML cells and address venetoclax/azacitidine resistance in acute myeloid leukemia. IND submission planned for early 2027.
- **AMB-066** — A potent CSF1R-targeting monoclonal antibody in development for colorectal cancer minimal residual disease (CRC MRD), co-developed with MD Anderson Cancer Center. First patient dosed in a Phase 2a study in early 2025.
- **AMB-05X** — A potent monoclonal antibody against CSF1R for tenosynovial giant cell tumor (TGCT), granted FDA Fast Track designation and EMA PRIME designation.
- **AMB-051** — CSF1R-targeting antibody program for tenosynovial giant cell tumor (TGCT).

## Achievements

- Built a three-program oncology pipeline from a single clinically-validated CSF1R antibody.
- Secured FDA Fast Track and EMA PRIME designations for its CSF1R antibody in TGCT.
- Dosed first patient in a Phase 2a colorectal cancer MRD study (early 2025).
- Established co-development agreements with MD Anderson Cancer Center.
- Licensed Lonza's SYNtecan exatecan linker-payload platform for AMB-104 (June 2026).
- Founded in partnership with Amgen, which holds a minority stake.

## Latest updates

- **2026-06** — AmMax Bio licensed Lonza's exatecan-based SYNtecan linker-payload platform for its AMB-104 antibody-drug conjugate for hematological cancers; IND submission planned for early 2027.
- **2026-06** — Travis Read appointed President and Chief Operating Officer.
- **2024-12** — AmMax Bio and MD Anderson announced agreements to advance development of AMB-066 in colorectal cancer patients with minimal residual disease.
- **2024-09** — AmMax Bio presented at the Oppenheimer Healthcare Private Company Showcase.
- **2025-01** — First patient dosed in Phase 2a study evaluating AMB-066 in colorectal cancer minimal residual disease.

## Links

- Website: https://ammaxbio.com
- LinkedIn: http://www.linkedin.com/company/ammax-bio-inc

---

Profile page: https://yespress.io/ammax-bio-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-14